UNLABELLED: This study was designed to evaluate the radiation dosimetry in human subjects for a new radiopharmaceutical, N-(3-(18)F-fluoropropyl)-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropane ((18)F-FPCIT). The goal was to determine a limiting dose consistent with accepted guidelines for use in clinical studies and to compare the radiation burden with other agents such as (123)I-FPCIT, (18)F-fluorodopa, and (18)F-FDG. METHODS: Dynamic PET scans of the urinary bladder were obtained in 6 subjects; 2 subjects had brain scans and 5 subjects had scans of the thorax or abdomen. Regions of interest were placed over composite images of each organ for which activity was visualized to generate time-activity curves. Doses were calculated from residence times using the MIRDOSE3 program. RESULTS: The critical organ for dosimetry is the urinary bladder wall with a dose of 0.0586 +/- 0.0164 mGy/MBq. The dose comes primarily (97.2%) from activity in the urinary bladder contents. The dose is lower than any of the other agents used commonly in PET to assess dopaminergic function. The effective dose equivalent (0.0120 mGy/MBq) is also lower than comparable compounds. CONCLUSION: (18)F-FPCIT has favorable dosimetry when compared with other agents used to study dopaminergic function. Doses as high as 853 MBq (23 mCi) may be given to adult patients and remain within accepted guidelines.
UNLABELLED: This study was designed to evaluate the radiation dosimetry in human subjects for a new radiopharmaceutical, N-(3-(18)F-fluoropropyl)-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropane ((18)F-FPCIT). The goal was to determine a limiting dose consistent with accepted guidelines for use in clinical studies and to compare the radiation burden with other agents such as (123)I-FPCIT, (18)F-fluorodopa, and (18)F-FDG. METHODS: Dynamic PET scans of the urinary bladder were obtained in 6 subjects; 2 subjects had brain scans and 5 subjects had scans of the thorax or abdomen. Regions of interest were placed over composite images of each organ for which activity was visualized to generate time-activity curves. Doses were calculated from residence times using the MIRDOSE3 program. RESULTS: The critical organ for dosimetry is the urinary bladder wall with a dose of 0.0586 +/- 0.0164 mGy/MBq. The dose comes primarily (97.2%) from activity in the urinary bladder contents. The dose is lower than any of the other agents used commonly in PET to assess dopaminergic function. The effective dose equivalent (0.0120 mGy/MBq) is also lower than comparable compounds. CONCLUSION: (18)F-FPCIT has favorable dosimetry when compared with other agents used to study dopaminergic function. Doses as high as 853 MBq (23 mCi) may be given to adult patients and remain within accepted guidelines.
Authors: Akihiro Takano; Christer Halldin; Andrea Varrone; Per Karlsson; Nils Sjöholm; James B Stubbs; Magnus Schou; Anu J Airaksinen; Johannes Tauscher; Balázs Gulyás Journal: Eur J Nucl Med Mol Imaging Date: 2007-11-14 Impact factor: 9.236
Authors: Vijay Dhawan; William Robeson; David Bjelke; Thomas Chaly; Kristin Graf; Matthew Hellman; Limei Zhuo; Meggan Mackay; David Eidelberg Journal: J Nucl Med Date: 2015-04-30 Impact factor: 10.057
Authors: Jeffrey S Stehouwer; Lauryn M Daniel; Ping Chen; Ronald J Voll; Larry Williams; Susan J Plott; John R Votaw; Michael J Owens; Leonard Howell; Mark M Goodman Journal: J Med Chem Date: 2010-08-12 Impact factor: 7.446
Authors: Jin Kyoung Oh; Ik Dong Yoo; Ye Young Seo; Yong An Chung; Ie Ryung Yoo; Sung Hoon Kim; In Uk Song Journal: Nucl Med Mol Imaging Date: 2011-10-14
Authors: Yasuyuki Kimura; Fabrice G Siméon; Jun Hatazawa; P David Mozley; Victor W Pike; Robert B Innis; Masahiro Fujita Journal: Eur J Nucl Med Mol Imaging Date: 2010-06-29 Impact factor: 9.236
Authors: Minyoung Oh; Narae Lee; Chanwoo Kim; Hye Joo Son; Changhwan Sung; Seung Jun Oh; Sang Ju Lee; Sun Ju Chung; Chong Sik Lee; Jae Seung Kim Journal: Sci Rep Date: 2021-07-22 Impact factor: 4.379